Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in hypothalamic obesity
2022-004107-32Phase 2
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jan 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setmelanotide in hypothalamic obesity (HO), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Proportion of patients with at least 5% BMI reduction from baseline at approximately 16 weeks.
02
Drugs
setmelanotide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on 2022-004107-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004107-32.